You are here

  • Home
  • Archive
  • Volume 10, Issue 4
  • Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion

Authors

  • Camille Le Gall Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The NetherlandsDepartment of Tumor Immunology, Oncode Institute, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Anna Cammarata Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Lukas de Haas Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Iván Ramos-Tomillero Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The NetherlandsInstitute for Chemical Immunology, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Jorge Cuenca-Escalona Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Kayleigh Schouren Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Zacharias Wijfjes Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The NetherlandsInstitute for Chemical Immunology, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Anouk M D Becker Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Johanna Bödder Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Yusuf Dölen Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The NetherlandsDepartment of Tumor Immunology, Oncode Institute, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • I Jolanda M de Vries Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Carl G Figdor Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The NetherlandsDepartment of Tumor Immunology, Oncode Institute, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Georgina Flórez-Grau Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Martijn Verdoes Department of Tumor Immunology, Radboudumc Radboud Institute for Molecular Life Sciences, Nijmegen, The NetherlandsInstitute for Chemical Immunology, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Martijn Verdoes; Martijn.Verdoes{at}radboudumc.nl; Dr Georgina Flórez-Grau; Georgina.Florez-Grau{at}radboudumc.nl
View Full Text

Citation

Le Gall C, Cammarata A, de Haas L, et al
Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion
Journal for ImmunoTherapy of Cancer 2022;10:e004309. doi: 10.1136/jitc-2021-004309

Publication history

  • Accepted March 15, 2022
  • First published April 15, 2022.
Online issue publication 
August 25, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.